Physician profile
Michael A Remillard
NPI 1255444089
$1,655.38
in general payments reported to CMS, 2019-2025
27 companies · $46.98 in 2025
The $46.98 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $497 · 2020: $86.64 · 2021: $430 · 2022: $250 · 2023: $178 · 2024: $167 · 2025: $46.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $391.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $217.07 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $165.07 | 2021-2023 | |
| Lilly USA, LLC | $147.79 | 2021-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $141.60 | 2021-2024 | Trelegy Ellipta, Shingrix |
| Amgen INC. | $104.96 | 2019-2024 | Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $100.58 | 2019-2022 | |
| Astellas Pharma US INC | $91.38 | 2019-2021 | |
| Biogen, INC. | $90.98 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $90.53 | 2019-2021 | |
| Pfizer INC. | $72.75 | 2019 | |
| Abbott Laboratories | $70.31 | 2021-2023 | Freestyle Libre 2 |
| Acadia Pharmaceuticals INC | $46.40 | 2019-2020 | |
| Allergan, INC. | $42.17 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.66 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $29.21 | 2024 | Airsupra |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $28.55 | 2019 | |
| Supernus Pharmaceuticals, INC. | $21.44 | 2021 | |
| Phathom Pharmaceuticals, INC. | $20.63 | 2024 | Voquezna |
| Sunovion Pharmaceuticals INC. | $20.52 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $18.73 | 2019 | |
| Idorsia Pharmaceuticals US INC | $16.89 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.82 | 2022 | |
| Ucb, INC. | $13.23 | 2019 | |
| Avanir Pharmaceuticals, INC. | $13.12 | 2021 | |
| Rhodes Pharmaceuticals L.P. | $12.64 | 2019 | |
| Almatica Pharma LLC | $12.25 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Remillard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.